EUVIMEDEUVIMED entdecken
Systematische Übersicht

AI-Driven Neuroadaptive Vision Therapy for Amblyopia: A Systematic Review

Tharani P, Dinesh Kumar T, Sethupathi A, Srija S

International Journal of Drug Delivery Technology · 01.06.2026 · 16 (41s)

DOI: 10.25258/ijddt.16.41s.99 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 01.06.2026. Verfasst von Tharani P und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

One of the main causes of avoidable monocular vision impairment is amblyopia. Patching and other traditional therapies have drawbacks, such as low compliance and little binocular improvement. Neuroadaptive, binocularfocused therapies that may offer more individualized and interesting rehabilitation are made possible by emerging technologies like artificial intelligence (AI), eye tracking, and immersive VR/AR.

Objective

To examine the most recent research on AI-enabled neuroadaptive vision therapy for amblyopia, including gamified, digital/dichoptic, and VR/AR methods, with an emphasis on clinical results, safety, and constraints.

Methods

Clinical trials and reviews on AI-based diagnostic or treatment tools for amblyopia were found using a systematic search (2000–2025) of PubMed, PMC, and peer-reviewed literature. A narrative synthesis was carried out because of the variation in interventions and results. Results: • Diagnostics: AI-driven stereovision tests outperformed conventional techniques with great accuracy (AUC 0.97–0.98). • Digital binocular therapy: Children's BCVA, stereoacuity, and contrast sensitivity were all enhanced by gamified dichoptic and adaptive digital treatments. • VR/AR therapy: In older children and adults, VR head-mounted dichoptic training enhanced stereoacuity; BCVA improvements differed. Accessibility is increasing, according to ongoing AR-based home therapy experiments. • Comparative efficacy: VR dichoptic treatment produced BCVA increases comparable to patching, according to a randomized experiment (1.32 vs. 1.0 lines over 20 weeks). • Safety/compliance: High tolerance with few systemic or ocular side effects was reported in studies.

Conclusion

AI-driven neuroadaptive vision treatment is a promising improvement for improving both acuity and binocular function in amblyopia. However, small study sizes, inconsistent methods, and brief follow-up times limit the available evidence. Before widespread clinical acceptance, extensive, robust randomized trials are required.

Zitieren

APA

P, T., T, D. K., A, S., & S, S. (2026). AI-Driven Neuroadaptive Vision Therapy for Amblyopia: A Systematic Review. International Journal of Drug Delivery Technology, 16(41s). https://doi.org/10.25258/ijddt.16.41s.99

Vancouver

P T, T DK, A S, S S. AI-Driven Neuroadaptive Vision Therapy for Amblyopia: A Systematic Review. International Journal of Drug Delivery Technology. 2026;16(41s). doi:10.25258/ijddt.16.41s.99

BibTeX
@article{P2026,
  author = {P, Tharani and T, Dinesh Kumar and A, Sethupathi and S, Srija},
  title = {AI-Driven Neuroadaptive Vision Therapy for Amblyopia: A Systematic Review},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {41s},
  doi = {10.25258/ijddt.16.41s.99}
}
Kostenlos starten →